Feature | June 24, 2015

Early-Stage Breast Cancer Imaging Rates for Metastatic Cancer High Despite Guidelines

Canadian study finds 86 percent of women undergo pre- or postoperative imaging for peace of mind, against recommendations

early-stage breast cancer, metastatic, guidelines, CMAJ, University of Ottawa

June 24, 2015 - Most women with early-stage breast cancer will undergo imaging to determine if the cancer has metastasized, despite international guidelines that recommend against testing, found a study in Canadian Medical Association Journal (CMAJ).

Guidelines from the American Society of Clinical Oncology, Cancer Care Ontario and the National Comprehensive Cancer Network recommend against imaging for metastatic cancer in asymptomatic women with stage I or II breast cancer; this is because the likelihood of metastases is low, at 0.2 percent and 1.2 percent, respectively, and the chance of false-positive findings are high. Unnecessary investigation can result in harm because false-positive results can lead to more invasive tests, treatment delays and increased anxiety.

"Despite guidelines against imaging to detect radiologically-evident distant metastases, our results show that this practice is very common among patients with early-stage breast cancer in Ontario," wrote Mark Clemons, M.D., an oncologist at The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, with coauthors.

A study of 26,547 women in Ontario diagnosed with stage I or stage II breast cancer between 2007 and 2012 found that 86 percent (22,811) underwent at least one imaging test to detect whether the cancer had metastasized. Imaging was performed in about 80 percent of women with stage I breast cancer and about 93 percent (11,882) in those with stage II. The average number of tests performed per patient was 3.7 in the pre- and postoperative periods. Surgeons and oncologists ordered the most tests, with surgeons ordering 74 percent of preoperative tests and oncologists ordering about 41 percent of postoperative tests.

The researchers found that the use of advanced imaging, such as computed tomography, magnetic resonance imaging and positron emission tomography, to investigate possible metastases, has increased and now comprises 41 percent of all initial tests.

There was also variability in use of imaging between geographic regions in the province and between community hospitals and academic institutions.

"If guideline recommendations are to be implemented in practice, additional knowledge translation strategies are needed, as dissemination of clinical practice guidelines alone is not an effective method of changing physician practice behaviors. ... These strategies will also require patient engagement," concluded the authors

In a related commentary, Daniel Rayson, M.D., and Geoff Porter, M.D., of Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, wrote, "Both teams [surgical and oncological] may order tests to reassure and support the anxious, newly diagnosed patient and her loved ones - clearly laudable goals. Patients are often blindsided by a cancer diagnosis and rely on their medical team to be as certain as possible that their disease can be cured and they are not dying."

However, testing has a cascading effect, because recommendations for more confirmatory tests, increased wait times for results and possible treatment can heighten patient and family anxiety as well as increase costs and use of healthcare resources.

"It is the responsibility of physicians to be knowledge brokers between the evidence-based guidance and their patients. To do so effectively takes time, energy and good interdisciplinary communication. ... For most patients with newly diagnosed stage I and II breast cancer, reflexively ordering staging investigations does not help relieve stress, nor does it detect disease," stated the commentary authors.

For more information: www.cmaj.ca

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init